Market Analysis

[MARKET ANALYSIS] Bourses firm as energy looks through geopolitical escalation; AstraZeneca hit after trial, Tech outperforms

StockNow breaking-news AI analysis

European markets rose as investors focused on potential US-Iran deals despite military strikes. AstraZeneca plunged 9% on trial failure, while Deutz gained on a major acquisition.

News detail

European bourses (STOXX 600 +0.5%/Euro Stoxx 50 +1.0%) opened with gains as markets generally look through the geopolitical escalation. FTSE 100 is the laggard as energy majors pull back and AstraZeneca slumps, IBEX 35 is the clear outperformer after US-Spain trade-related underperformance on Wednesday. To briefly recap events overnight, tit-for-tat strikes were conducted by the US on around 90 Iranian targets, and the IRGC fired on military bases in Bahrain and Kuwait. Markets remain optimistic, focusing on remarks from US President Trump, who said he spoke with Iran, and that they want to make a deal. Sectors opened with a positive, risk-on bias and continue this way in quiet EU trade. Tech and Basic Resources outperform, while Energy and Utilities are the laggards. Stock specifics include: AstraZeneca (-9%) CARDIO-TTRansform Phase III trial did not meet the primary endpoint of efficacy around CV mortality; Deutz (5.5%), To acquire  FFG Flensburger Fahrzeugbau Gesellschaft for EUR 1.6bln. US equity futures conform to the positive sentiment seen across the pond,  albeit to a lesser extent. Tech heavy NQ is the outperformer, while ES and RTY also perform well.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more